Due to the well-known immune suppressive activity of DPP4 [107] and its association with decreased lymphocyte trafficking, a combination therapy of LINC01132 shRNAs and PD-L1 inhibitor was tested in the Hepa1–6 xenograft model, showing a clear tumor regression with respect to LINC01132 silencing alone and the highest positivity for CD8+ infiltrates, proving the efficacy of LINC01132 knockdown together with a PD-L1 blockade [108]. This evidence concerns the gene DPP4 and neoplasm.